Last reviewed 2026-04-22 · How we verify

ASKC202+ Limertinib

ASKC202 is a bispecific antibody targeting EGFR and c-MET, combined with limertinib, a third-generation EGFR tyrosine kinase inhibitor, to overcome resistance in EGFR-mutant lung cancer.

ASKC202 is a bispecific antibody targeting EGFR and c-MET, combined with limertinib, a third-generation EGFR tyrosine kinase inhibitor, to overcome resistance in EGFR-mutant lung cancer. Used for EGFR-mutant non-small cell lung cancer with acquired resistance to prior EGFR inhibitors.

At a glance

Mechanism of action

ASKC202 bridges EGFR and c-MET signaling pathways to prevent compensatory activation, while limertinib irreversibly inhibits mutant EGFR including T790M resistance mutations. This dual approach targets both primary EGFR-driven proliferation and c-MET-mediated escape mechanisms that drive acquired resistance in advanced lung cancer.

Approved indications

• EGFR-mutant non-small cell lung cancer with acquired resistance to prior EGFR inhibitors

Common side effects

• Diarrhea
• Rash
• Nausea
• Fatigue

Key clinical trials

• Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 (PHASE1)
• ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.